NCT06449703View on ClinicalTrials.gov

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

June 16, 2024

Study Completion Date

June 16, 2024

Conditions
Healthy
Interventions
DRUG

insulin degludec/liraglutide

Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.

DRUG

Xultophy®

Xultophy®

Trial Locations (1)

Unknown

RECRUITING

the First Hospital of Jilin University, Jilin

All Listed Sponsors
lead

Tonghua Dongbao Pharmaceutical Co.,Ltd

INDUSTRY